ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 650

Decreased Severity of Pristane Induced Lupus in miR155 Deficient Mice

Harald Leiss1, Wilhelm Salzberger2, Irina Gessl1, Barbara Schwarzecker3, Nicolas Kozakowski4, Stephan Blüml1, Antonia Puchner1, Birgit Niederreiter3, Carl-Walter Steiner5, Josef Smolen3 and Georg H. Stummvoll2, 1Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Rheumatology, Medical University of Vienna, Vienna, Austria, 3Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 4Department of Pathology, Medical University of Vienna, Vienna, Austria, 5Division of Rheumatology, Medical University of Vienna, Vienna, Austria

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: MicroRNA and SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose

MicroRNAs (miRs) are an important class of regulators of gene expression that are associated with a variety of biological functions. Deregulation of endogenous miR155 was observed in many autoimmune conditions, including SLE. We herein examine the role of miR155 in the development of systemic manifestations in murine pristane induced lupus by evaluating the severity of organ involvement and assessing serum antibody-levels and T helper cell homeostasis.

Methods

MiR155-deficient (miR155-PIL) and C57/Bl6 (WT-PIL) mice were injected i.p. with 0.5ml of pristane or PBS as control (WT-PBS). In order to observe the effects of miR155 deficiency in fully developed SLE, we analyzed the mice 8 months after induction.

A blinded specialist appraised histological features of GN using the composite kidney biopsy score (KBS). Histological features of pneumonitis were quantified by an image analysis system: Lungs were scored for the severity of perivascular inflammation by analyzing the numbers of affected vessels and the area of the inflammatory infiltrate. In order to assess the composition of these infiltrates, specimens were stained with B220 (B), CD3 (T), Neu7/4 (neutrophils) and F4/80 (macrophages) and analyzed by cell-identification algorithms for nuclear segmentation (HistoQuest¨).

Lymphocytes were isolated from spleens and analyzed separately for each mouse by standard FACS procedures. For analysis of the Th1, 2 or 17 subsets, respectively, cells were re-stimulated in vivo with anti-CD3 and anti-CD28abs.

Results

Lungs were affected in both pristane-treated groups, but not in controls. MiR155-PIL had reduced lupus severity as indicated by significantly decreased perivascular inflammatory area with B cells being the most prominent inflammatory cell type in the HistoQuest analysis (Fig. 1A). Without showing clinical abnormalities WT-PIL had a more severe renal involvement in the kidney biopsy score than miR-PIL (Fig. 1B). Corresponding with reduced severity in organ involvement, miR155-PIL had lower serum levels of anti-dsDNA-abs (Fig. 1C), decreased frequencies of CD4+ cells (14.24 ± 0.7587 vs. 18.04 ± 1.075, p=0.01) and slightly lower frequencies of activated CD4+CD25+Foxp3– cells (1.539 ± 0.1279 vs. 1.838 ± 0.2259, p=ns.). Interestingly, also frequencies of CD4+CD25+Foxp3+ regulatory T cells were lower in Mir155-PIL (1.689 ± 0.1388 vs. 2.375 ± 0.2320, p=0.03). Upon restimulation, CD4+ cells showed a more pronounced Th2 and Th17 response in WT-PIL, but no significant differences in Th1 phenotype (Fig. 1D).

Conclusion

MiR155 deficiency in PIL mice did not prevent the development of disease, but was associated with less severe lung and kidney involvement, lower serum auto-abs levels and lower Th17 and Th2 frequencies when analyzed in fully established PIL after 8 months. Thus, antagonisation of miR155 might be a beneficial future approach in treating SLE.

Beschreibung: Macintosh HD:Users:Dino:Dropbox:Labor:Output:Abstracts:2014:EULAR2014 Fig Mir155.tiff


Disclosure:

H. Leiss,
None;

W. Salzberger,
None;

I. Gessl,
None;

B. Schwarzecker,
None;

N. Kozakowski,
None;

S. Blüml,
None;

A. Puchner,
None;

B. Niederreiter,
None;

C. W. Steiner,
None;

J. Smolen,
None;

G. H. Stummvoll,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-severity-of-pristane-induced-lupus-in-mir155-deficient-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology